Mizuho initiates Teladoc at Neutral, says BetterHelp biz a drag

Mizuho initiated coverage on Teladoc (TDOC) with a Neutral rating and a $10 price target, citing steady growth in its core Integrated Care and B2B virtual care segments, and the potential long-term benefits from the UpLift acquisition, projected to reach $80 million in revenue by 2028. However, the firm expressed significant concern over persistent near-term attrition in Teladoc's BetterHelp business, which accounts for 35-40% of revenue, due to high customer churn, acquisition costs exceeding $550 million annually, and projected EBITDA margin decline from 19% (2020) to 5-6% (2025). Mizuho believes BetterHelp's ongoing challenges will keep TDOC trading at a discount, requiring clear signs of stabilization or greater UpLift synergy for investor confidence despite slightly higher earnings estimates than consensus.

Analysis

Mizuho's initiation of coverage on Teladoc (TDOC) with a Neutral rating and a $10 price target highlights a significant operational divergence within the company. While the core B2B Integrated Care and chronic condition management segments exhibit stable growth, this is overshadowed by severe challenges in the BetterHelp division, which constitutes 35-40% of total revenue. The primary concern is BetterHelp's high customer attrition, with users averaging only two to three sessions, leading to unsustainable annual acquisition costs exceeding $550 million. This dynamic is forecast to compress BetterHelp's EBITDA margins from 19% in 2020 down to 5-6% by 2025, effectively negating positive performance elsewhere and justifying a discounted valuation relative to peers. The recent UpLift acquisition is viewed as a potential long-term remedy for the behavioral health franchise, with revenue projected to grow from approximately $15 million in 2024 to over $80 million by 2028. However, the market is unlikely to reward the stock until there is concrete evidence of stabilization in BetterHelp's performance or clear synergies from the UpLift integration.

Key Decisions for Investors

• Investors should weigh the stability in Teladoc's core B2B business against the significant and ongoing deterioration of the BetterHelp segment, which faces high churn and severe margin compression.
• It is critical to monitor BetterHelp's key performance indicators, particularly customer attrition rates and acquisition costs, as any sign of stabilization is the primary catalyst for a potential stock re-rating.
• Consider the UpLift acquisition as a long-term option for growth, but recognize its financial contribution is unlikely to offset the material, near-term profitability drag from the struggling BetterHelp division.